Renal Anemia – Unmet Need – Detailed, Expanded Analysis (US & EU) 2019

September 2019

Physicians treating renal anemia are limited to iron supplements and erythropoiesis-stimulating agents (ESAs), which, although effective, have significant drawbacks. The hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected to launch during the study period and appear to be able to effectively, safely, and conveniently improve renal anemia. However, to succeed, these novel therapies will have to convince physicians and payers of their safety and efficacy benefits compared with current therapies. In addition, HIF-PH inhibitors will face reimbursement hurdles, competition from biosimilar ESAs, and an increasingly stringent regulatory environment. Given that the drug development pipeline for renal anemia is relatively weak, substantial unmet need and considerable market opportunity remain.


  • What are the treatment drivers and goals for renal anemia?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do ESAs perform on key treatment drivers and goals for renal anemia?
  • What are the prevailing areas of unmet need and opportunity in renal anemia?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European nephrologists for a hypothetical new renal anemia drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European nephrologists fielded in June 2019.

Key companies: Roche, Amgen, Janssen, Akebia Therapeutics, Otsuka Pharmaceuticals, Astellas Pharma, AstraZeneca, GlaxoSmithKline, Bayer, Fibrogen, Japan Tobacco

Key drugs: Aranesp, Mircera, Procrit/Epogen/Eprex/Erypo, HIF-PH inhibitors, ESAs.


  • Target Product Profile (TPP) simulator based on conjoint analysis methodology.
  • Stated versus derived importance of product attributes on prescribing behavior.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet needs in the indication and related indications.
  • Analysis of remaining drug development opportunities.


Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

launch Related Market Assessment Reports